Search for Clinical Trial Results

Sponsored By

Desmoid Tumor - 23 Studies Found

Status Study
Withdrawn Study Name: Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
Condition:
  • Desmoid Tumors
  • Fibromatosis

Date: 2009-09-15
Interventions: Drug: Hydroxyurea Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients w
Completed Study Name: Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
Condition: Desmoid Tumor
Date: 2006-02-06
Interventions: Drug: imatinib mesylate
Completed Study Name: National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)
Condition: Aggressive Fibromatosis
Date: 2016-07-15
Interventions:
  • Procedure: biopsy pre-therapeu
Completed Study Name: Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
Condition: Desmoid Type-fibromatosis
Date: 2015-01-28
Interventions: Drug: Toremifene Patients will receive 60 mg daily and then 180 daily in case of progression
Completed Study Name: Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients
Condition: Desmoid-type Fibromatosis
Date: 2015-01-28
Interventions: Other: Observational approach Patients will be placed under wait and see approach without any specific t
Active, not recruiting Study Name: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Desmoid-Type Fibromatosis
Date: 2014-02-17
Interventions:
  • Other: Laboratory Biomarker Analysis

Completed Study Name: Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors
Condition:
  • The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an
  • Adjuvant Ther
    Date: 2013-06-26
    Interventions: Drug: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
Available Study Name: Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
Condition:
  • Neoplasm
  • Desmoid Tumor

Date: 2016-11-02
Interventions: Drug: PF-03084014 Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084
Active, not recruiting Study Name: A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Condition: Fibromatosis
Date: 2015-07-08
Interventions: Drug: Imatinib Imatinib 400 mg/day until disease progression
Completed Study Name: Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Condition:
  • Hormone Receptor-Positive Breast
  • Gynecologic